التفاصيل البيبلوغرافية
| العنوان: |
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. |
| المؤلفون: |
Singh, Simron, Ferone, Diego, Capdevila, Jaume, Chan, Jennifer Ang, de Herder, Wouter W., Halperin, Daniel, Mailman, Josh, Hellström, Lisa, Liedman, Hanna, Svedberg, Agneta, Tiberg, Fredrik |
| المصدر: |
Trials; 6/21/2024, Vol. 25 Issue 1, p1-2, 2p |
| مصطلحات موضوعية: |
CLINICAL trials, SAFETY, MEDICAL assistance |
| مستخلص: |
This document is a correction notice for an article titled "Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET." The correction addresses an error in the original article regarding the administration of CAM2029 compared to octreotide LAR and lanreotide ATG. The corrected statement clarifies that CAM2029 can be self-administered by the patient or carer using a pre-filled pen, while the administration of octreotide LAR and lanreotide ATG requires medical assistance. The correction also provides references for further information on the administration requirements of lanreotide ATG and octreotide LAR. [Extracted from the article] |
|
Copyright of Trials is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder